
Deutsche Bank cuts Oxford BioMedica target by 26% after weak revenue and delays
Deutsche Bank downgraded Oxford BioMedica from 'buy' to 'hold' and cut its target price by 26% to 595p due to slower revenue growth and delays in its programmes. The bank noted operational issues at the company's Durham site and weaker visibility ahe...


